Icosavax discovers what caused its lead vaccine to flop, and doesn't see it affecting follow-up programs

Aayushi Pratap

News Reporter

Seattle-based Icosavax was one of the companies in the rat race to develop Covid-19 vaccine shots better than Pfizer and Moderna. However, when clinical trials …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Icosavax discovers what caused its lead vaccine to flop, and doesn't see it affecting follow-up programs

Aayushi Pratap

News Reporter

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

Icosavax dis­cov­ers what caused its lead vac­cine to flop, and does­n't see it af­fect­ing fol­low-up pro­grams

Aayushi Pratap

News Reporter

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Icosavax discovers what caused its lead vaccine to flop, and doesn't see it affecting follow-up programs

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs